Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte
pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe
psoriasis.